Catabasis Pharmaceuticals, Inc. reports financial results for the second quarter ended 30 June 2021 and provides a corporate update. “We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with HAE to prevent attacks,” says Jill C. [...]
At the presentation of the financial results for the second quarter ended 30 June 2021, Intellia Therapeutics, Inc. President and CEO John Leonard, M.D., says: “This quarter marked an exciting new chapter for Intellia. We presented the first clinical data in history supporting precision editing of a disease-causing gene within the body following a single, [...]
“BioCryst is in an outstanding position, both near-term and long-term, with growing revenue from a strong Orladeyo launch in the U.S. and more approvals and launches of Orladeyo around the globe”, says President and CEO Jon Stonehouse at BioCryst Pharmaceuticals, Inc.'s presentation of the financial results for the second quarter ended 30 June 2021. Program [...]
At the presentation of the Pharming Group N.V. preliminary (unaudited) financial report for the first six months of 2021, CEO Sijmen de Vries comments: “Post period, we delivered on one of our strategic objectives to strengthen our longer-term HAE pipeline, through a collaboration with Orchard Therapeutics, to develop and commercialize the pre-clinical ex-vivo autologous hematopoietic stem [...]
CSL Behring receives U.S. Food and Drug Administration (FDA) approval for its supplemental request for co-packaging of a convenience administration kit along with its product Berinert, indicated for the treatment of acute abdominal, facial, or laryngeal attacks of HAE in adult and pediatric patients. Combination product packaging will improve the patient experience by providing ready-to-go, [...]
From the Ionis Pharmaceuticals, Inc. financial results for the second quarter of 2021 and recent business achievements: "Since our last quarterly update, we continued to execute on our strategic objectives to prepare for multiple commercial launches, expand our drug delivery capabilities and advance new products towards the market. Looking ahead, we expect data from multiple [...]
At the presentation of the financial results for the second quarter ended 30 June 2021, Pharvaris co-founder and CEO Berndt Modig says: “We made significant clinical advancements this quarter as we seek to offer novel treatments to HAE patients that are both convenient and efficacious. The data presented recently at two medical meetings continue to demonstrate [...]
Pharming Group N.V. has entered into an exclusive licence agreement with NewBridge Pharmaceuticals for the distribution of Ruconest (conestat alfa) in the Middle East and North Africa. NewBridge, headquartered in Dubai, United Arab Emirates, is a regional specialty company, with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and [...]
In an operational update released together with the financial results for the fiscal year ended 30 April 2021, KalVista Pharmaceuticals, Inc. CEO Andrew Crockett says: “This past fiscal year we made great strides in providing data to support the development of the candidates in our oral HAE franchise. Now we are at an important inflection point as [...]
At the EAACI Hybrid Congress 2021, KalVista Pharmaceuticals, Inc. presented its oral drug candidates. Data presentations included a late-breaking poster for the Phase 2 data for KVD900, KalVista’s lead drug program for oral on-demand treatment of HAE attacks, two posters on the prevalence and clinical management of normal C1-INH HAE in the US, and two posters on [...]
